NEWS
July 2021
Safety Phamacology: Core Battery Reloaded Nonclinical Safety Assessment; Study Design By Roman Goetz
June 2021
Are you ready to SEND your non-clinical data to FDA? Regulatory, FDA By Marko Repic
April 2021
Classification of Borderline Products in the EU: Are all nucleic acid-based products gene therapies? Regulatory, Nucleic Acid-Based Therapies By Anika Schroeter
Nucleic Acid-based products are gene therapies, aren’t they? The answer to this question is not as straight forward as one might think, but will substantially influence the overall development strategy of a product candidate. Indeed, in the past, European regulators classified nucleic acid-based products either as gene therapy or as small molecule / biologic or as vaccine based on the current definition laid out in EU Directive 2001/83/EC. However, a discussion on the European level is ongoing indicating a change and streamlining in the current thinking. Read more
February 2021
A Frequently Asked Question in Non-Clinical Development: Is there a Need for (Bio)Analytical Method Validation under GLP Conditions? Regulatory, Method Validation By Roman Goetz
Bioanalytical methods (as well as dose formulation assays) used in GLP-compliant nonclinical studies (as well as dose formulation assays) should be validated. Regulatory requirements on GLP-compliance of method validation are different in the ICH geographies. Here, we are discussing the requirements and their implications on method validation. Read more
December 2020
Establishing a Safe and Efficacious Human Starting Dose: A Hurdle for Cell and Gene Therapies Human Starting Dose, Cell and Gene Therapy Products By Anika Schroeter and Marko Repic
Definition of a human starting dose is a challenging step in every development process, representing a particular hurdle for gene and cell therapy products. In contrast to small molecules or biologics, there is no specific guidance, providing clear recommendations on how to determine a human starting dose. Individual, product-tailored and innovative approaches are needed, which require a thorough understanding of the indication, mode of action and potential risks related to the product. Read further to learn more about specific approaches and our experience with different cell and gene therapy products. Read more
Newsletter Archive
2020/12 | 2021/01 | 2021/02 | 2021/03 | 2021/04Legal Notice
If you choose to provide us with your email address or any other personally identifiable information, we will use it only to send you our newsletter or respond to your query.For further information please read our Privacy Policy.